Skip to main content
Top
Published in: Respiratory Research 1/2010

Open Access 01-12-2010 | Research

Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency

Authors: James M Duckers, Dennis J Shale, Robert A Stockley, Nichola S Gale, Bronwen AJ Evans, John R Cockcroft, Charlotte E Bolton

Published in: Respiratory Research | Issue 1/2010

Login to get access

Abstract

Background

Determining the presence and extent of co-morbidities is fundamental in assessing patients with chronic respiratory disease, where increased cardiovascular risk, presence of osteoporosis and low muscle mass have been recognised in several disease states. We hypothesised that the systemic consequences are evident in a further group of subjects with COPD due to Alpha-1 Antitrypsin Deficiency (A1ATD), yet are currently under-recognised.

Methods

We studied 19 patients with PiZZ A1ATD COPD and 20 age, sex and smoking matched controls, all subjects free from known cardiovascular disease. They underwent spirometry, haemodynamic measurements including aortic pulse wave velocity (aPWV), an independent predictor or cardiovascular risk, dual energy X-ray absorptiometry to determine body composition and bone mineral density.

Results

The aPWV was greater in patients: 9.9(2.1) m/s than controls: 8.5(1.6) m/s, p = 0.03, despite similar mean arterial pressure (MAP). The strongest predictors of aPWV were age, FEV1% predicted and MAP (all p < 0.01). Osteoporosis was present in 8/19 patients (2/20 controls) and was previously unsuspected in 7 patients. The fat free mass and bone mineral density were lower in patients than controls (p < 0.001).

Conclusions

Patients with A1ATD related COPD have increased aortic stiffness suggesting increased risk of cardiovascular disease and evidence of occult musculoskeletal changes, all likely to contribute hugely to overall morbidity and mortality.
Literature
1.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: Role of comorbidities. Eur Respir J 2006,28(6):1245–57.CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: Role of comorbidities. Eur Respir J 2006,28(6):1245–57.CrossRefPubMed
2.
go back to reference Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009,33(5):1165–85.CrossRefPubMed Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009,33(5):1165–85.CrossRefPubMed
3.
go back to reference McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007,62(5):411–5.CrossRefPubMedPubMedCentral McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007,62(5):411–5.CrossRefPubMedPubMedCentral
4.
go back to reference Blanco I, Bustillo EF, Rodriguez MC: Distribution of alpha1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet 2001,60(6):431–41.CrossRefPubMed Blanco I, Bustillo EF, Rodriguez MC: Distribution of alpha1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet 2001,60(6):431–41.CrossRefPubMed
5.
go back to reference McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, Macnee W: Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007,176(12):1208–14.CrossRefPubMedPubMedCentral McAllister DA, Maclay JD, Mills NL, Mair G, Miller J, Anderson D, Newby DE, Murchison JT, Macnee W: Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007,176(12):1208–14.CrossRefPubMedPubMedCentral
6.
go back to reference Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M: Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008,134(6):1244–9.CrossRefPubMed Ohara T, Hirai T, Muro S, Haruna A, Terada K, Kinose D, Marumo S, Ogawa E, Hoshino Y, Niimi A, Chin K, Mishima M: Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 2008,134(6):1244–9.CrossRefPubMed
8.
go back to reference Ortiz-Muñoz G, Houard X, Martín-Ventura JL, Ishida BY, Loyau S, Rossignol P, Moreno JA, Kane JP, Chalkley RJ, Burlingame AL, Michel JB, Meilhac O: HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009,23(9):3129–39.CrossRefPubMedPubMedCentral Ortiz-Muñoz G, Houard X, Martín-Ventura JL, Ishida BY, Loyau S, Rossignol P, Moreno JA, Kane JP, Chalkley RJ, Burlingame AL, Michel JB, Meilhac O: HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009,23(9):3129–39.CrossRefPubMedPubMedCentral
9.
go back to reference Aldonyte R, Jansson L, Janciauskiene S: Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro. BMC Cell Biol 2004, 5:11.CrossRefPubMedPubMedCentral Aldonyte R, Jansson L, Janciauskiene S: Concentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitro. BMC Cell Biol 2004, 5:11.CrossRefPubMedPubMedCentral
10.
go back to reference Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, European Network for Non-invasive Investigation of Large Arteries: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006,27(21):2588–605.CrossRefPubMed Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, European Network for Non-invasive Investigation of Large Arteries: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006,27(21):2588–605.CrossRefPubMed
11.
go back to reference Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006,113(5):664–70.CrossRefPubMed Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006,113(5):664–70.CrossRefPubMed
12.
go back to reference Ahlgren AR, Piitulainen E, Sonesson B, Lanne T: Changes in aortic wall stiffness in men with alpha 1-antitrypsin deficiency. Eur J Vasc Endovasc Surg 1997,14(4):252–7.CrossRefPubMed Ahlgren AR, Piitulainen E, Sonesson B, Lanne T: Changes in aortic wall stiffness in men with alpha 1-antitrypsin deficiency. Eur J Vasc Endovasc Surg 1997,14(4):252–7.CrossRefPubMed
13.
go back to reference Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M, Diabetes Atherosclerosis Intervention Study Investigators: Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003,23(4):644–9.CrossRefPubMed Talmud PJ, Martin S, Steiner G, Flavell DM, Whitehouse DB, Nagl S, Jackson R, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Humphries SE, Syvänne M, Diabetes Atherosclerosis Intervention Study Investigators: Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003,23(4):644–9.CrossRefPubMed
14.
go back to reference Stakisaitis D, Basys V, Benetis R: Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis? Med Sci Monit 2001,7(4):701–11.PubMed Stakisaitis D, Basys V, Benetis R: Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis? Med Sci Monit 2001,7(4):701–11.PubMed
15.
go back to reference Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ: Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004,170(12):1286–93.CrossRefPubMed Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ: Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004,170(12):1286–93.CrossRefPubMed
16.
go back to reference Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ: Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007,175(12):1259–65.CrossRefPubMed Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ: Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007,175(12):1259–65.CrossRefPubMed
17.
go back to reference American Thoracic Society Committee on the proficiency Standards for Clinical Pulmonary Function Laboratories: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002, 166:111–117.CrossRef American Thoracic Society Committee on the proficiency Standards for Clinical Pulmonary Function Laboratories: Guidelines for the Six-Minute Walk Test. Am J Respir Crit Care Med 2002, 166:111–117.CrossRef
18.
go back to reference Jones PW, Quirk FH, Baveystock CM: The St George's Respiratory Questionnaire. Respiratory Medicine 1991, 85:25–31.CrossRefPubMed Jones PW, Quirk FH, Baveystock CM: The St George's Respiratory Questionnaire. Respiratory Medicine 1991, 85:25–31.CrossRefPubMed
19.
go back to reference Wilson PW, Paffenbarger RS, Morris JN, Havlik RJ: Assessment methods for physical activity and physical fitness in population studies: report of a NHLBI workshop. Am Heart J 1986,111(6):1177–92.CrossRefPubMed Wilson PW, Paffenbarger RS, Morris JN, Havlik RJ: Assessment methods for physical activity and physical fitness in population studies: report of a NHLBI workshop. Am Heart J 1986,111(6):1177–92.CrossRefPubMed
20.
21.
go back to reference World Health Organisation: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1984, 84. World Health Organisation: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1984, 84.
22.
go back to reference Holick MF: High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006,81(3):353–73.CrossRefPubMed Holick MF: High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006,81(3):353–73.CrossRefPubMed
23.
go back to reference Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA: Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999,160(6):1968–75.CrossRefPubMed Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA: Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999,160(6):1968–75.CrossRefPubMed
24.
go back to reference Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010,375(9709):132–40.CrossRef Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010,375(9709):132–40.CrossRef
25.
go back to reference Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE: Arterial stiffness in chronic inflammatory diseases. Hypertension 2005,46(1):194–9.CrossRefPubMed Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, Crow MK, Sammaritano L, Levine DM, Shankar BA, Moeller E, Salmon JE: Arterial stiffness in chronic inflammatory diseases. Hypertension 2005,46(1):194–9.CrossRefPubMed
26.
go back to reference Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, Kohansal R, Burghuber OC: Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008,178(12):1211–8.CrossRefPubMed Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, Kohansal R, Burghuber OC: Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008,178(12):1211–8.CrossRefPubMed
27.
go back to reference Coulson JM, Rudd JH, Duckers JM, Rees JI, Shale DJ, Bolton CE, Cockcroft JR: Excessive Aortic Inflammation in Chronic Obstructive Pulmonary Disease: An 18F-FDG PET Pilot Study. J Nucl Med 2010,51(9):1357–60.CrossRefPubMed Coulson JM, Rudd JH, Duckers JM, Rees JI, Shale DJ, Bolton CE, Cockcroft JR: Excessive Aortic Inflammation in Chronic Obstructive Pulmonary Disease: An 18F-FDG PET Pilot Study. J Nucl Med 2010,51(9):1357–60.CrossRefPubMed
28.
go back to reference Chignard M, Hazouard E, Renesto P, Laine A, Guidet B, Offenstadt G: Plasma antiproteinase screen and neutrophil-mediated platelet activation. A major role played by alpha 1 antitrypsin. Biochim Biophys Acta 1994,1224(3):433–40.CrossRefPubMed Chignard M, Hazouard E, Renesto P, Laine A, Guidet B, Offenstadt G: Plasma antiproteinase screen and neutrophil-mediated platelet activation. A major role played by alpha 1 antitrypsin. Biochim Biophys Acta 1994,1224(3):433–40.CrossRefPubMed
29.
go back to reference Aldonyte R, Hutchinson TE, Jin B, Brantly M, Block E, Patel J, Zhang J: Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. COPD 2008,5(3):153–62.CrossRefPubMed Aldonyte R, Hutchinson TE, Jin B, Brantly M, Block E, Patel J, Zhang J: Endothelial alpha-1-antitrypsin attenuates cigarette smoke induced apoptosis in vitro. COPD 2008,5(3):153–62.CrossRefPubMed
30.
go back to reference Janciauskiene S, Dominaitiene R, Sternby NH, Piitulainen E, Eriksson S: Detection of circulating and endothelial cell polymers of Z and wild type alpha 1-antitrypsin by a monoclonal antibody. J Biol Chem 2002,277(29):26540–6.CrossRefPubMed Janciauskiene S, Dominaitiene R, Sternby NH, Piitulainen E, Eriksson S: Detection of circulating and endothelial cell polymers of Z and wild type alpha 1-antitrypsin by a monoclonal antibody. J Biol Chem 2002,277(29):26540–6.CrossRefPubMed
31.
go back to reference Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S: Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 2004,45(6):587–92.CrossRefPubMed Aldonyte R, Jansson L, Ljungberg O, Larsson S, Janciauskiene S: Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology 2004,45(6):587–92.CrossRefPubMed
32.
go back to reference Dahl M, Tybjaerg-Hansen A, Sillesen H, Jensen G, Steffensen R, Nordestgaard BG: Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha(1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003,107(5):747–52.CrossRefPubMed Dahl M, Tybjaerg-Hansen A, Sillesen H, Jensen G, Steffensen R, Nordestgaard BG: Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha(1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003,107(5):747–52.CrossRefPubMed
33.
go back to reference Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006,113(9):1213–25.CrossRefPubMed Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators CAFE Steering Committee and Writing Committee: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006,113(9):1213–25.CrossRefPubMed
34.
go back to reference McEniery CM, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockcroft JR, Wilkinson IB, Anglo-Cardiff Collaborative Trial Investigators: Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008,51(6):1476–82.CrossRefPubMed McEniery CM, McDonnell B, Munnery M, Wallace SM, Rowe CV, Cockcroft JR, Wilkinson IB, Anglo-Cardiff Collaborative Trial Investigators: Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. Hypertension 2008,51(6):1476–82.CrossRefPubMed
35.
go back to reference Anthonisen NR, Connett JE, Enright PL, Manfreda J: Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002,166(3):333–9.CrossRefPubMed Anthonisen NR, Connett JE, Enright PL, Manfreda J: Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002,166(3):333–9.CrossRefPubMed
36.
go back to reference Maciewicz RA, Warburton D, Rennard SI: Can increased understanding of the role of lung development and aging drive new advances in chronic obstructive pulmonary disease? Proc Am Thorac Soc 2009,6(7):614–7.CrossRefPubMed Maciewicz RA, Warburton D, Rennard SI: Can increased understanding of the role of lung development and aging drive new advances in chronic obstructive pulmonary disease? Proc Am Thorac Soc 2009,6(7):614–7.CrossRefPubMed
37.
38.
go back to reference Vivodtzev I, Minet C, Wuyam B, Borel JC, Vottero G, Monneret D, Baguet JP, Lévy P, Pépin JL: Significant improvement in arterial stiffness after endurance training in COPD patients. Chest 2010,137(3):585–92.CrossRefPubMed Vivodtzev I, Minet C, Wuyam B, Borel JC, Vottero G, Monneret D, Baguet JP, Lévy P, Pépin JL: Significant improvement in arterial stiffness after endurance training in COPD patients. Chest 2010,137(3):585–92.CrossRefPubMed
39.
go back to reference Duckers JM, Bolton CE, Evans BA, Evans W, Stone MD, Shale DJ: Osteoporosis and loss of bone mineral density in corticosteroid-naïve male patients with chronic obstructive pulmonary disease [abstract]. Thorax 2008,63(suppl vii):A23. S48 Duckers JM, Bolton CE, Evans BA, Evans W, Stone MD, Shale DJ: Osteoporosis and loss of bone mineral density in corticosteroid-naïve male patients with chronic obstructive pulmonary disease [abstract]. Thorax 2008,63(suppl vii):A23. S48
Metadata
Title
Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency
Authors
James M Duckers
Dennis J Shale
Robert A Stockley
Nichola S Gale
Bronwen AJ Evans
John R Cockcroft
Charlotte E Bolton
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2010
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-11-173

Other articles of this Issue 1/2010

Respiratory Research 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.